Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Neoplasms 2Zollinger-Ellison Syndrome 1Vomiting 1Prostatic Neoplasms 1Pancreatitis 1Pancreatic Neoplasms 1Ototoxicity 1Osteosarcoma 1Neoplasm Metastasis 1Gastrinoma 1Duodenal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Pantoprazole × Clear all
NCT03948477 2022-05-25

PantoCIN

University of Auckland, New Zealand

Phase 2 Completed
160 enrolled
Breast

Breast Neoplasms, Neoplasms, Vomiting

NCT01848457 2020-03-16

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Children's Hospital of Philadelphia

Phase 2 Completed
13 enrolled 15 charts
Sarcoma

Ototoxicity, Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡